CapsoVision (CV) Q4 2025 earnings review
Top-Line Growth Overshadowed by Surging Cash Burn
CapsoVision's Q4 results present a stark contrast between commercial progress and financial reality. While revenue grew 13% YoY to $3.9 million driven by CapsoCam Plus volume, operating expenses ballooned by 47% to $9.4 million. The heavy investments in Canon CMOS sensor development and clinical trials are eating through capital at an alarming rate. With gross margins retreating to 50% and year-end cash down to $10.1 million, the company was forced to execute a $14 million post-close equity raise in March 2026—just eight months after its July 2025 IPO. Growth is present, but the path to profitability remains highly opaque.
🐂 Bull Case
CapsoCam Plus continues to gain traction, crossing 161,000 cumulative patients. Full-year revenue grew 15% to $13.6M, purely driven by core product volume increases.
The 510(k) submission for the in-house AI-assisted module is a major milestone. If approved, it could significantly enhance clinical value, workflow efficiency, and potentially pricing power.
🐻 Bear Case
OpEx is scaling much faster than revenue. Q4 OpEx of $9.4M is nearly 2.5x the quarter's revenue, resulting in severe operating losses that demand constant capital infusions.
New account growth has sharply decelerated from 75% YoY in Q2, to 31% in Q3, down to just 16% in Q4, signaling that the easiest market share grabs may be in the rearview.
⚖️ Verdict: 🔴
Bearish. The core product is selling, but the business model currently lacks leverage. Skyrocketing R&D costs, margin compression, and heavy reliance on dilutive equity raises overshadow the mid-teens revenue growth.
Key Themes
Severe Deceleration in New Account Growth
A critical red flag emerged in the commercial pipeline: new account growth is rapidly decelerating. After a massive 75% YoY surge in 25Q2 and a solid 31% in 25Q3, Q4 new account growth dropped to just 16%. Since volume is the primary revenue driver, this steep drop-off in customer acquisition velocity threatens future top-line momentum.
Gross Margin Compression
Gross margins are moving in the wrong direction, decelerating from 55% in Q2, to 54% in Q3, and landing at 50% in Q4. For a medical device company with high R&D burdens, a 50% gross margin leaves virtually no room to absorb operating expenses. Management has not detailed whether this is due to pricing pressure, manufacturing costs, or mix.
AI Integration and Pipeline Maturation
Innovation remains CapsoVision's primary long-term catalyst. The company successfully submitted a 510(k) to the FDA for its AI-assisted module for CapsoCam Plus. Furthermore, the Canon CMOS sensor development and ongoing dialogue with the FDA regarding the next-generation CapsoCam Colon represent massive addressable market expansions, albeit at a heavy current cost.
Unsustainable Cash Burn Trajectory
Operating cash flow for FY25 was a negative $22.9M. Despite raising $23.4M net in a July 2025 IPO, the company ended the year with just $10.1M in cash. This forced a $14M private placement in March 2026. The aggressive R&D spend required to fund the Canon agreement and clinical trials is outpacing capital generation by a massive margin.
Other KPIs
Reversing/Deteriorating. Net loss widened substantially from $19.9M in FY24. Q4 alone represented an estimated $7.4M loss. The bulk of this expansion stems from a $6.4M YoY increase in operating expenses, highlighting the immense toll of operating as a newly public entity while funding heavy R&D.
Accelerating. Up $3.0M (+47%) YoY compared to Q4 2024. Driven primarily by development costs for the new CMOS image sensor with Canon Inc. and clinical trial activities for the AI technology and second-generation CapsoCam Colon.
Guidance
Management did not provide explicit quantitative financial guidance for revenue or earnings in FY26, citing a focus on 'disciplined execution' and advancing the capsule platform.
Management is targeting regulatory progression for the AI-assisted CapsoCam Plus module (510(k) submitted) and refining the regulatory pathway for CapsoCam Colon and the UGI pancreas initiative. Timing remains subject to FDA review cycles.
Key Questions
New Account Deceleration
New account growth dropped from 75% in Q2 to just 16% in Q4. Is this a function of market saturation in your current targets, sales force capacity, or tightening hospital capital budgets?
Margin Floor
Gross margins retreated to 50% this quarter after running in the mid-50s earlier in the year. What is driving this compression, and where do you expect margins to stabilize in FY26?
Capital Runway
With the recent $14M raise and an FY25 operating cash burn of nearly $23M, how many quarters of runway does the current balance sheet provide, assuming R&D spend remains elevated for the Canon partnership?
AI Monetization Strategy
Assuming FDA clearance for the AI-assisted module, do you plan to monetize this via a software-as-a-service (SaaS) subscription model, a per-procedure fee, or simply use it to drive hardware volume?